Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 4.64% and Operating profit at 14.49% over the last 5 years
2
The company has declared Positive results for the last 4 consecutive quarters
3
With ROE of 12.47%, it has a very attractive valuation with a 1.22 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 15,352 Million (Large Cap)
10.00
NA
2.31%
-0.20
10.20%
1.39
Revenue and Profits:
Net Sales:
2,191 Million
(Quarterly Results - Mar 2026)
Net Profit:
258 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.46%
0%
-8.46%
6 Months
-4.23%
0%
-4.23%
1 Year
6.49%
0%
6.49%
2 Years
31.86%
0%
31.86%
3 Years
22.05%
0%
22.05%
4 Years
12.8%
0%
12.8%
5 Years
-11.03%
0%
-11.03%
Zhejiang Medicine Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.64%
EBIT Growth (5y)
14.49%
EBIT to Interest (avg)
22.72
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.77
Tax Ratio
15.15%
Dividend Payout Ratio
30.66%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.04%
ROE (avg)
7.35%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.22
EV to EBIT
7.89
EV to EBITDA
5.25
EV to Capital Employed
1.27
EV to Sales
1.28
PEG Ratio
0.04
Dividend Yield
2.59%
ROCE (Latest)
16.10%
ROE (Latest)
12.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
2,190.90
2,185.30
0.26%
Operating Profit (PBDIT) excl Other Income
316.60
123.40
156.56%
Interest
4.80
6.40
-25.00%
Exceptional Items
-0.70
-16.70
95.81%
Consolidate Net Profit
258.40
-106.50
342.63%
Operating Profit Margin (Excl OI)
144.50%
-37.90%
18.24%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 0.26% vs -7.89% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 342.63% vs -143.97% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
8,837.80
9,325.60
-5.23%
Operating Profit (PBDIT) excl Other Income
1,639.30
2,018.30
-18.78%
Interest
32.10
35.40
-9.32%
Exceptional Items
-18.10
-112.90
83.97%
Consolidate Net Profit
760.20
1,020.30
-25.49%
Operating Profit Margin (Excl OI)
95.50%
138.80%
-4.33%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -5.23% vs 20.17% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -25.49% vs 268.61% in Dec 2024
About Zhejiang Medicine Co., Ltd. 
Zhejiang Medicine Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






